BP Targets Across CKM Stages
Investigators assess stage-specific outcomes, safety, and net benefit of intensive blood pressure control in cardiovascular-kidney-metabolic syndrome.
By
Kathryn Wighton
February 19, 2026
Clinical Scorecard: BP Targets Across CKM Stages
At a Glance
Category Detail
Condition Cardiovascular-Kidney-Metabolic Syndrome Key Mechanisms Intensive blood pressure control targeting <130/80 mmHg Target Population Participants aged 40 years or older with hypertension Care Setting Rural primary care facilities
Key Highlights
Intensive BP control associated with reduced major adverse cardiovascular events Primary composite outcome occurred less frequently with intensive therapy Stroke contributed the largest absolute risk reduction Net clinical benefit observed across all CKM stages All-cause mortality reduced in stages II and III Guideline-Based Recommendations
Diagnosis
Cardiovascular-kidney-metabolic syndrome stages defined per 2023 AHA framework Management
Implement a stepped-care antihypertensive algorithm targeting BP <130/80 mmHg Monitoring & Follow-up
Monitor for hypotension and adverse events during intensive treatment Risks
Increased risk of hypotension and potential kidney adverse events in stage III Patient & Prescribing Data
Patients with hypertension, specifically those at least stage II CKM
Achieved net systolic BP reductions of 21.4 to 26.2 mmHg
Clinical Best Practices
Utilize structured lifestyle counseling alongside medication access Consider potential limitations in extrapolating findings to urban settings Related Resources & Content
